High Index of Clinical Suspicion With Optimal Surgical Techniques and Adjuvant Radiotherapy Is Critical to Reduce Locoregional Disease Progression in Parathyroid Carcinoma

Selvan, Ben; Paul, Mazhuvenchery J.; Seshadri, M. S.; Thomas, Nihal; Paul, Thomas; Abraham, Deepak Thomas; Oommen, Regi; Shandhly, Nylla; John, Subhashini; Rajaratnam, Simon; Therese, Marie M.; Nair, Aravindan; Samuel, Prasanna Kumar

doi:10.1097/coc.0b013e31823a4924

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parathyroid carcinoma is resistant to chemotherapy. Radiotherapy has a limited role but may be used to treat metastases [15, 16]. Distant metastases occur in up to 50 % of patients and may take years to appear.…”

Section: Introductionmentioning

confidence: 99%

Parafibromin, Galectin‐3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Parafibromin, Galectin‐3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A few chemotherapy drugs were used in the metastatic setting, including cyclophosphamide, 5-fluorouracil and dacarbazine as single or combination therapies, but no survival benefit was demonstrated. Denosumab, a monoclonal antibody against RANKL (receptor activator of nuclear factor kappa-Β ligand) that inhibits osteoclast maturation, function, and survival can be useful in malignant hypercalcemia treatment [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Intrathyroidal parathyroid carcinoma: a case report and literature review

et al. 2021

View full text Add to dashboard Cite

Parathyroid carcinoma is an uncommon endocrine malignancy comprising 0.5%–2% of patients with primary hyperparathyroidism. The probability of an intrathyroidal location is low (0.2%) and make preoperative suspicion and diagnosis challenging. Less than 20 cases of intrathyroidal parathyroid carcinoma have been reported. We introduce a case of intrathyroidal parathyroid carcinoma mimicking a suspicious thyroid nodule, and review the literature, with a focus on the role of adjuvant radiotherapy.

show abstract

“…They do not recommend the use of RT as treatment for metastatic disease, and the authors emphasised the need for clinicians to understand possible risks associated with RT, such as increased difficulty of subsequent neck surgery. Munson et al (2003), Kirkby-Bott et al (2005), Selvan et al (2013) and Busaidy et al (2004), also recommend post-operative RT, supporting its use in reducing local recurrence rates. Apaydin et al (2021) suggest adjuvant radiotherapy to the neck to reduce the risk of local recurrence only in patients with microscopic residual parathyroid carcinoma.…”

Section: Radiotherapymentioning

confidence: 92%

Diagnosis and management of parathyroid carcinoma: a state-of-the-art review

Roser

Leca

Matta-Coelho

et al. 2023

Endocrine-Related Cancer

View full text Add to dashboard Cite

Parathyroid carcinoma is one of the least common endocrine malignancies, and accounts for approximately 1% of all patients with primary hyperparathyroidism. A systematic review of peer-reviewed literature published between January 2000 and March 2022 via Medline, Embase, Cochrane Central Register of Controlled Trials, EudraCT, ClinicalTrials.gov, CINAHL and SCOPUS was conducted. Manuscripts were eligible if they included data on adult non-pregnant populations with parathyroid carcinoma. No restrictions regarding interventions, comparators or duration of follow-up were imposed. Single case reports, reviews or meta-analyses were excluded. Outcomes of interest were molecular pathogenesis, clinical presentation, differential diagnosis, treatment, follow-up and overall survival. Study quality was evaluated using the Newcastle-Ottawa Scale for observational studies. Seventy-five studies were included from 17 countries, reporting on more than 3000 patients with parathyroid carcinoma. CDC73 mutation has been recognised as playing a pivotal role in molecular pathogenesis. Parathyroid carcinoma typically presents with markedly increased calcium and parathyroid hormone levels. The most frequently described symptoms were bone and muscle pain or weakness. En bloc resection remains the gold standard for the surgical approach. The five-year overall survival ranged from 60% to 93%, with resistant hypercalcaemia a significant cause of mortality. Emerging evidence indicating that targeted therapy, based on molecular biomarkers, presents a novel treatment option. The rarity of PC and need for personalised treatment warrants multidisciplinary management in a ‘centre of excellence’ with a track record in PC management.

show abstract

High Index of Clinical Suspicion With Optimal Surgical Techniques and Adjuvant Radiotherapy Is Critical to Reduce Locoregional Disease Progression in Parathyroid Carcinoma

Abstract: PTC should be suspected in the preoperative and intraoperative period. EBRT may reduce local recurrence by 65%. Parafibromin staining with no more than 0 to 1+ intensity in 80% to 100% of cells can predict carcinoma with specificity up to 100%.

Cited by 7 publications

References 20 publications

Parafibromin, Galectin‐3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer

Parafibromin, Galectin‐3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer

Intrathyroidal parathyroid carcinoma: a case report and literature review

Diagnosis and management of parathyroid carcinoma: a state-of-the-art review

Contact Info

Product

Resources

About